HUP0400692A2 - Szubsztituált 7H-pirrolo[2,3-d]pirimidin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények - Google Patents
Szubsztituált 7H-pirrolo[2,3-d]pirimidin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyászati készítményekInfo
- Publication number
- HUP0400692A2 HUP0400692A2 HU0400692A HUP0400692A HUP0400692A2 HU P0400692 A2 HUP0400692 A2 HU P0400692A2 HU 0400692 A HU0400692 A HU 0400692A HU P0400692 A HUP0400692 A HU P0400692A HU P0400692 A2 HUP0400692 A2 HU P0400692A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- formula
- pyrrolo
- substituted
- pharmaceutical compositions
- Prior art date
Links
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical class N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 4
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract 2
- 229960005305 adenosine Drugs 0.000 abstract 2
- -1 hydroxycyclohexyl group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A találmány tárgyát adenozin A1, A2A és A3 receptorokat fajlagosangátló (XI) általános képletű, valamint (1609), (1610) és (1720)képletű vegyületek képezik. A találmány tárgya továbbá ezekalkalmazása az adenozin A1, A2A, és A3 receptorokkal kapcsolatosbetegségek kezelésére alkalmas gyógyszerek előállítására. A (XI)képletben R1NR2 együttes jelentése (442) vagy (443) képletű csoport,vagy R1=H és R2 jelentése hidroxi-ciklohexil-csoport, azzal amegkötéssel, hogy amennyiben -R1NR2 együttes jelentése (442) vagy(443) képletű csoport, akkor R5 jelentése hidrogénatom, metoxi-metil-,metil-, karboxicsoport, -CH2(NC5H8)(OH)(C6H5), -(CH2)2COOH, -CH2OCH2CONH2, -CH2O(CH2)2OH, -CH2OCH2COOH vagy -CH2OCH2COOCH3; vagyamennyiben R1=H és R2 jelentése hidroxi-cikloalkenil-csoport, akkor R5jelentése karboxi-, metixikarbonil-, aminokarbonil-csoport, -CH2(N2C3H3) vagy -CH2O(CH2)2OH. Ó
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/728,616 US7160890B2 (en) | 1999-12-02 | 2000-12-01 | Compounds specific to adenosine A3 receptor and uses thereof |
US09/728,607 US6664252B2 (en) | 1999-12-02 | 2000-12-01 | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof |
US09/728,316 US6680322B2 (en) | 1999-12-02 | 2000-12-01 | Compounds specific to adenosine A1 receptors and uses thereof |
PCT/US2001/045280 WO2002057267A1 (en) | 2000-12-01 | 2001-11-30 | Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0400692A2 true HUP0400692A2 (hu) | 2004-07-28 |
HUP0400692A3 HUP0400692A3 (en) | 2007-09-28 |
Family
ID=27419112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0400692A HUP0400692A3 (en) | 2000-12-01 | 2001-11-30 | Substituted 7h-pyrrolo[2,3-d]pyrimidine derivatives, their use and pharmaceutical compositions containing them |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP1347980A4 (hu) |
JP (1) | JP4579497B2 (hu) |
CN (1) | CN1263757C (hu) |
AP (1) | AP1893A (hu) |
AU (1) | AU2002248151B2 (hu) |
BR (1) | BR0115847A (hu) |
CA (1) | CA2430577A1 (hu) |
CZ (1) | CZ20031831A3 (hu) |
EA (1) | EA007254B1 (hu) |
HU (1) | HUP0400692A3 (hu) |
IL (1) | IL155962A0 (hu) |
ME (1) | MEP35308A (hu) |
MX (1) | MXPA03004717A (hu) |
NO (1) | NO327207B1 (hu) |
NZ (1) | NZ525885A (hu) |
OA (1) | OA13295A (hu) |
PL (1) | PL363245A1 (hu) |
WO (1) | WO2002057267A1 (hu) |
YU (1) | YU42703A (hu) |
ZA (1) | ZA200303729B (hu) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5090531A (en) * | 1990-01-10 | 1992-02-25 | Lord Corporation | Electrophoretic fluid differential |
BR9911612A (pt) | 1998-06-02 | 2001-02-06 | Osi Pharm Inc | Composições de pirrolo[2,3d]pirimidina e seus usos |
US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
DE10148883A1 (de) * | 2001-10-04 | 2003-04-10 | Merck Patent Gmbh | Pyrimidinderivate |
WO2003048120A2 (en) | 2001-11-30 | 2003-06-12 | Osi Pharmaceuticals, Inc. | 2-aryl pyrrologpyrimidines for a1 and a3 receptors |
EP1474147B1 (en) * | 2001-12-07 | 2010-05-05 | Vertex Pharmaceuticals Incorporated | Pyrimidine-based compounds useful as gsk-3 inhibitors |
US20030229067A1 (en) | 2001-12-20 | 2003-12-11 | Arlindo Castelhano | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use |
WO2003053366A2 (en) | 2001-12-20 | 2003-07-03 | Osi Pharmaceuticals, Inc. | Pyrimidine a2b selective antagonist compounds, their synthesis and use |
AU2003270701B2 (en) * | 2002-10-31 | 2009-11-12 | Amgen Inc. | Antiinflammation agents |
HUP0203976A3 (en) * | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
JP5606734B2 (ja) | 2006-04-25 | 2014-10-15 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
US20070260203A1 (en) * | 2006-05-04 | 2007-11-08 | Allergan, Inc. | Vasoactive agent intraocular implant |
TW200808819A (en) * | 2006-06-19 | 2008-02-16 | Solvay Pharm Gmbh | Use of adenosine A1 antagonists in radiocontrast media induced nephrophaty |
NZ585261A (en) | 2007-10-11 | 2011-10-28 | Astrazeneca Ab | Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors |
CA2711777A1 (en) | 2008-01-11 | 2009-08-13 | Natco Pharma Limited | Novel pyrazolo [3,4-d] pyrimidine derivatives as anti-cancer drugs |
AR070127A1 (es) | 2008-01-11 | 2010-03-17 | Novartis Ag | Pirrolo - pirimidinas y pirrolo -piridinas |
BR112013025410A2 (pt) | 2011-04-01 | 2016-12-20 | Astrazeneca Ab | tratamento terapêutico |
PT2785349T (pt) | 2011-11-30 | 2019-12-11 | Astrazeneca Ab | Tratamento combinado de cancro |
AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
CA2873723A1 (en) * | 2012-06-07 | 2013-12-12 | F. Hoffmann-La Roche Ag | Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase |
EP3010917B1 (en) * | 2013-06-21 | 2018-01-31 | Zenith Epigenetics Ltd. | Novel substituted bicyclic compounds as bromodomain inhibitors |
CN109939113B (zh) | 2013-06-21 | 2022-02-15 | 恒翼生物医药科技(上海)有限公司 | 双环溴结构域抑制剂 |
US9855271B2 (en) | 2013-07-31 | 2018-01-02 | Zenith Epigenetics Ltd. | Quinazolinones as bromodomain inhibitors |
WO2016087942A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Corp. | Substituted pyridines as bromodomain inhibitors |
US10710992B2 (en) | 2014-12-01 | 2020-07-14 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
US10292968B2 (en) | 2014-12-11 | 2019-05-21 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
CA2966450A1 (en) | 2014-12-17 | 2016-06-23 | Olesya KHARENKO | Inhibitors of bromodomains |
JP6742323B2 (ja) * | 2015-01-20 | 2020-08-19 | 无▲錫▼福祈制▲薬▼有限公司Wuxi Fortune Pharmaceutical Co.,Ltd | Jak阻害剤 |
TR201909694T4 (tr) | 2015-04-29 | 2019-07-22 | Wuxi Fortune Pharmaceutical Co Ltd | Janus kinaz (jak) inhibitörleri. |
MX2017013797A (es) | 2015-05-29 | 2018-03-21 | Wuxi Fortune Pharmaceutical Co Ltd | Inhibidor de janus quinasa. |
CN105771672B (zh) * | 2016-04-18 | 2018-03-02 | 天津工业大学 | 一种抗污染抗菌芳香聚酰胺反渗透复合膜及制备方法 |
JP7071389B2 (ja) * | 2017-03-07 | 2022-05-18 | グアンジョウ マキシノベル ファーマシューティカルズ カンパニー リミテッド | アミノピリミジン縮合5員複素環化合物、その中間体、製造方法、薬物組成物および使用 |
CN108017584B (zh) * | 2017-06-20 | 2021-03-23 | 南开大学 | A3腺苷受体的小分子拮抗剂 |
EP3802540A1 (en) * | 2018-06-04 | 2021-04-14 | Exscientia Ltd | Pyrazolopyrimidine compounds as adenosine receptor antagonists |
CN110128316B (zh) * | 2019-05-22 | 2021-08-31 | 北京大学深圳研究生院 | 5位取代的β-脯氨酸及其衍生物的制备方法 |
CN110272373B (zh) * | 2019-07-02 | 2022-07-29 | 天津国际生物医药联合研究院 | 一种具有选择性的腺苷a1受体拮抗剂及其应用 |
CN114085178A (zh) * | 2021-12-29 | 2022-02-25 | 苏州楚凯药业有限公司 | 一种4-甲基-1-丙基-2-氨基-1h-吡咯-3-腈的制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6765008B1 (en) * | 1992-12-17 | 2004-07-20 | Pfizer Inc | Pyrrolopyrimidines as CRF antagonists |
US5780450A (en) * | 1995-11-21 | 1998-07-14 | Alcon Laboratories, Inc. | Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage |
BR9911612A (pt) * | 1998-06-02 | 2001-02-06 | Osi Pharm Inc | Composições de pirrolo[2,3d]pirimidina e seus usos |
PT1246623E (pt) * | 1999-12-02 | 2006-12-29 | Osi Pharm Inc | Compostos específicos para o receptor de adenosina a1,a2a e a3 e as suas utilizações |
WO2003048120A2 (en) * | 2001-11-30 | 2003-06-12 | Osi Pharmaceuticals, Inc. | 2-aryl pyrrologpyrimidines for a1 and a3 receptors |
-
2001
- 2001-11-30 NZ NZ525885A patent/NZ525885A/en active IP Right Revival
- 2001-11-30 HU HU0400692A patent/HUP0400692A3/hu unknown
- 2001-11-30 AU AU2002248151A patent/AU2002248151B2/en not_active Ceased
- 2001-11-30 MX MXPA03004717A patent/MXPA03004717A/es active IP Right Grant
- 2001-11-30 EP EP01997029A patent/EP1347980A4/en not_active Ceased
- 2001-11-30 OA OA1200300148A patent/OA13295A/en unknown
- 2001-11-30 CN CNB018224601A patent/CN1263757C/zh not_active Expired - Fee Related
- 2001-11-30 ME MEP-353/08A patent/MEP35308A/xx unknown
- 2001-11-30 YU YU42703A patent/YU42703A/sh unknown
- 2001-11-30 JP JP2002557944A patent/JP4579497B2/ja not_active Expired - Fee Related
- 2001-11-30 CZ CZ20031831A patent/CZ20031831A3/cs unknown
- 2001-11-30 AP APAP/P/2003/002807A patent/AP1893A/en active
- 2001-11-30 IL IL15596201A patent/IL155962A0/xx unknown
- 2001-11-30 CA CA002430577A patent/CA2430577A1/en not_active Abandoned
- 2001-11-30 WO PCT/US2001/045280 patent/WO2002057267A1/en active IP Right Grant
- 2001-11-30 BR BR0115847-3A patent/BR0115847A/pt not_active Application Discontinuation
- 2001-11-30 PL PL01363245A patent/PL363245A1/xx not_active Application Discontinuation
- 2001-11-30 EA EA200300628A patent/EA007254B1/ru not_active IP Right Cessation
-
2003
- 2003-05-14 ZA ZA200303729A patent/ZA200303729B/en unknown
- 2003-06-02 NO NO20032482A patent/NO327207B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2002057267A1 (en) | 2002-07-25 |
CN1489590A (zh) | 2004-04-14 |
AP1893A (en) | 2008-09-23 |
NO20032482D0 (no) | 2003-06-02 |
NO327207B1 (no) | 2009-05-11 |
IL155962A0 (en) | 2003-12-23 |
JP4579497B2 (ja) | 2010-11-10 |
CN1263757C (zh) | 2006-07-12 |
CA2430577A1 (en) | 2002-07-25 |
CZ20031831A3 (cs) | 2004-05-12 |
ZA200303729B (en) | 2004-05-14 |
EA007254B1 (ru) | 2006-08-25 |
EP1347980A1 (en) | 2003-10-01 |
HUP0400692A3 (en) | 2007-09-28 |
NZ525885A (en) | 2005-01-28 |
MEP35308A (en) | 2011-02-10 |
EA200300628A1 (ru) | 2003-12-25 |
AP2003002807A0 (en) | 2003-06-30 |
PL363245A1 (en) | 2004-11-15 |
OA13295A (en) | 2007-04-13 |
NO20032482L (no) | 2003-07-28 |
YU42703A (sh) | 2006-03-03 |
MXPA03004717A (es) | 2004-06-30 |
BR0115847A (pt) | 2004-02-25 |
AU2002248151B2 (en) | 2008-02-21 |
JP2004517896A (ja) | 2004-06-17 |
EP1347980A4 (en) | 2005-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0400692A2 (hu) | Szubsztituált 7H-pirrolo[2,3-d]pirimidin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények | |
UY24560A1 (es) | Derivados arilos de la pirimidina útiles como antagonistas 5ht2b selectivos | |
SE9701398D0 (sv) | Novel compounds | |
MXPA02007942A (es) | Derivados de pirrolopirimidinona, procesos de preparacion y uso. | |
AP2002002561A0 (en) | 5-HT receptor ligards and uses thereof. | |
NZ522326A (en) | Adenosine A2A receptor antagonists | |
MXPA01006474A (es) | Derivados colquinol como agentes perjudiciales vasculares. | |
CA2503900A1 (en) | Purine compounds and use thereof as cannabinoid receptor ligands | |
DOP2002000429A (es) | Imidazotriazinas | |
AR004516A1 (es) | Derivados de pirimidina, su uso, procedimientos para prepararlos y medicamentos que los contienen | |
IL114003A (en) | 1,4,6-Trisubstituted 1H-pyrrolo[2,3-b]pyridine and 1-H-pyrazolo[3,4-b] pyridine derivatives and pharmaceutical compositions containing them and some intermediates for their preparation | |
ES2128735T3 (es) | Composiciones farmaceuticas que comprenden un antagonista de opiaceos y de sales de calcio y su uso para el tratamiento de patologias en las que intervienen las endorfinas. | |
ECSP067111A (es) | Derivados de pirido-pirimidina, su preparación, su aplicación en terapéutica | |
ATE211138T1 (de) | Beta-carbolin-derivate als melatonin-agonisten, ihre herstellungsverfahren und verwendung als arzneimittel | |
HUP0302874A2 (hu) | Eljárás risperidon előállítására | |
CY1109808T1 (el) | Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α | |
ES2144239T3 (es) | Derivados de vitamina d con sustituyentes en c-25, procedimiento para su preparacion, productos intermedios y la utilizacion para la preparacion de medicamentos. | |
HUP0002311A2 (hu) | Ergolinszármazékok és szomatosztatin receptorként való alkalmazásuk | |
MXPA02009643A (es) | Sintesis acortada de derivados de 3,3-diarilpropilamina. | |
HUP0203943A2 (hu) | Eljárás 9-es helyzetben helyettesített guaninszármazékok előállítására és ezek alkalmazása | |
HUP9904027A2 (hu) | P-Amino-fenol-származékok alkalmazása neurodegeneratív megbetegedések kezelésére alkalmas gyógyszerkészítmények előállítására | |
MY134026A (en) | ?-carboline derivatives and its pharmaceutical use against depression and anxiety | |
ES2191449T3 (es) | Derivados de ciclopentabenzofurano y su uso. | |
HUP0100048A2 (hu) | Arilszubsztituált piperazinszármazékok, alkalmazásuk gyógyszerkészítmények előállítására és a vegyületeket tartalmazó gyógyszerkészítmények | |
DE69927251D1 (de) | Verfahren zur herstellung von purinderivaten und dessen zwischenprodukte |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |